Molecular Imaging: Page 7

PET/MRI may improve diagnosis of Cushing disease
By Will Morton
PET/MRI could become the diagnostic method of choice over MRI alone for identifying small pituitary tumors associated with Cushing disease.
March 29, 2024
T1-weighted postgadolinium MR images (A and C) and F-18 FET-PET/MR images (B and D) centered at pituitary before (A and B) and after (C and D) transsphenoidal surgery. This patient with Cushing disease showed clear focal uptake (B) but no clear lesion on previously obtained and accompanying MRI (A). Postoperative tissue analysis did confirm resection of small pituitary adenoma/PitNET, and postoperative F-18 FET-PET showed no residual uptake (D). Image courtesy of the Journal of Nuclear Medicine.
The rise of theranostics: Part 1 -- Gaining momentum
By Liz Carey
FDA-approved radiopharmaceuticals have energized the field of theranostics. In part 1 of a series, experienced theranostics leaders offer implications of the latest clinical trials, how a theranostics clinic works, and advice for introducing theranostics.
March 19, 2024
Team members from the theranostics clinic under University of Texas Health Science Center at San Antonio's Department of Radiology show one aspect of a Pluvicto infusion treatment. The L block lead shield over the syringe helps protect certified nuclear medicine technologist James Johnson (left), and nuclear radiologist Penny Vroman, MD (right), from radiation emitted by the drug. (Photo courtesy of UT Health San Antonio Department of Radiology)
Can cardiac PET/CT ā€˜revolutionizeā€™ heart care?
By Will Morton
PET/CT is poised to become a key tool for imaging the coronary arteries as a clinical imaging exam that can reveal early warning signs of fatal conditions when patients present with symptoms of chest pain.
March 25, 2024
Heart Attack
Targeted radiopharmaceuticals offer new hope for longer 'healthspans'
By Mark Crockett, MD
Precision radiopharmaceuticals accurately target tumors while minimizing damage to healthy tissue, presenting an opportunity to extend not just lifespans but ā€œhealthspans,ā€ Mark Crockett, MD, explains in this article.
March 15, 2024
Isotopes1
Groups aim to standardize nuclear medicine imaging of CV infections
By Will Morton
Eleven medical associations have released guidance on the use of PET/CT and SPECT/CT for patients with cardiovascular (CV) infections.
March 15, 2024
Heart
Cannabis may influence bowel motility
By Will Morton
Physicians, health care providers, and medical staff caring for patients who use cannabis should be familiar with the effects of the drug on gut motility, a recent report advises.
March 11, 2024
Cannabis
Hold off on the Egg McMuffins before GES tests, experts say
By Will Morton
Nuclear medicine technologists are being advised that not just any meal works for patients before gastric emptying scintigraphy (GES).
March 7, 2024
Stomach
IMV: PET scan volumes continue to grow
By Davin Korstjens
The total volume of PET scans increased 10.2% year over year in 2023, according to the newly published IMV 2024 PET Market Summary Report.
March 7, 2024
Pet Scan
PET lung scan times could be cut by half
By Will Morton
Dynamic PET scans acquired in half the time of normal scans appear clinically feasible for patients with lung lesions.
March 6, 2024
A 60-year-old male patient with clinical suspicion of lung cancer. PET/CT scan showed FDG-avid pulmonary nodules in the upper lobe of the left lung (red arrow), with a size of 2.2 × 1.3 cm, SUVmax of 12.2, Ki-65 min of 0.016 ml/g/min, and Ki-30 min of 0.014 ml/g/min. Surgical pathology confirmed a granulomatous lesion. In addition, PET/CT scan showed many FDG-avid lung nodules in the mediastinum. (A, static PET maximum intensity projection; B, static PET SUV image; C, static PET/CT fusion image; D, dynamic PET Ki-65 min image; E, dynamic PET Ki-30 min image). Image courtesy of EJNMMI Physics.
Is ā€˜theragnomicsā€™ the future in molecular imaging?
By Will Morton
Combining theranostics and radiomics ā€“ a new concept termed ā€œtheragnomicsā€ ā€“ could be the key to realizing the full potential of molecular imaging of cancer patients.
March 6, 2024
Molecular Imaging
PET links impaired sleep in Alzheimerā€™s disease patients to tau protein
By Will Morton
PET scans have revealed specific brain pathology that may drive sleep disturbances in patients with Alzheimerā€™s disease.
February 13, 2024
A Dpatient
PET reveals brainā€™s energy demands during walking
By Will Morton
A group in England has established PET imaging as a new approach for studying gait ā€“ an excellent indicator of physical, emotional, and mental health.
February 9, 2024
Data analysis validation. Panel A: Image and line profile through the bottle on scans 1 (top) and 2 (middle), and the difference image (bottom) calculated according to Equation 3. Panel B: Data from a representative participant showing the effect of the dose correction on the PETWALK image using Equation 1 when applied to co-registered images in native subject space. The images were then warped to standard Montreal Neurological Institute (MNI) space Top: PETSTAND, middle – uncorrected PETWALK, bottom – corrected PETWALK. The color bar shows image intensity across the three images. Image courtesy of NeuroImage.
Previous Page
Page 7 of 597
Next Page